Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
uniQure (QURE) has shared an announcement.
uniQure N.V. has reached a significant milestone by administering the first dose in a Phase I/IIa clinical trial of AMT-191, their experimental treatment for Fabry disease. This progress may interest investors and those following biotech advancements, highlighting the company’s ongoing efforts to combat this genetic disorder.
Learn more about QURE stock on TipRanks’ Stock Analysis page.
